ConductScience.org, home

Paper39802403

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?

Wang W and 8 others. Genes Dis, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? Papers, record 39802403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39802403

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
PubMed
Journal
Genes Dis
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.63
iCite
Revised in PubMed
2026-10-20
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang WWei
2Du YYi
3Datta SSayantap
4Fowler JFJosef F
5Sang HTHannah T
6Albadari NNajah
7Li WWei
8Foster JJennifer
9Zhang RRuiwen

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA186662NCI NIH HHSUnited StatesR01CA186662PubMedNIH RePORTER
R01 CA214019NCI NIH HHSUnited StatesR01CA214019PubMed and NIHNIH RePORTER

Download CSV of grants

References196

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127586230The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.Invest New Drugs2016https://conductscience.org/library/papers/27586230PubMed
215720185p53-independent activities of MDM2 and their relevance to cancer therapy.Curr Cancer Drug Targets2005https://conductscience.org/library/papers/15720185PubMed
39419352Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.Proc Natl Acad Sci U S A1998https://conductscience.org/library/papers/9419352PubMed
434565342Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.BMC Cancer2021https://conductscience.org/library/papers/34565342PubMed
52997622L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.Nature1985https://conductscience.org/library/papers/2997622PubMed
621862876Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.Cell Cycle2011https://conductscience.org/library/papers/21862876PubMed
721876694Targeting angiogenesis for controlling neuroblastoma.J Oncol2012https://conductscience.org/library/papers/21876694PubMed
835018218Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.Oncotarget2022https://conductscience.org/library/papers/35018218PubMed
929311926Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.Front Pharmacol2017https://conductscience.org/library/papers/29311926PubMed
1014751837Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.Ann N Y Acad Sci2003https://conductscience.org/library/papers/14751837PubMed
112842250Confirmation of the assignment of MYCL to chromosome 1 in humans and its position relative to RH, UMPK, and PGM1.Genomics1988https://conductscience.org/library/papers/2842250PubMed
1227394681Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.J Control Release2016https://conductscience.org/library/papers/27394681PubMed
1319111882Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.Cancer Cell2009https://conductscience.org/library/papers/19111882PubMed
1431869746Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.Transl Oncol2020https://conductscience.org/library/papers/31869746PubMed
1531988297Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells.Cell Death Dis2020https://conductscience.org/library/papers/31988297PubMed
1629527331Targeting oncogenic Myc as a strategy for cancer treatment.Signal Transduct Target Ther2018https://conductscience.org/library/papers/29527331PubMed
1734003079MYCN amplification levels in primary retinoblastoma tumors analyzed by Multiple Ligation-dependent Probe Amplification.Ophthalmic Genet2021https://conductscience.org/library/papers/34003079PubMed
1826497213Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.Oncotarget2015https://conductscience.org/library/papers/26497213PubMed
1933034426The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.Cancer Med2020https://conductscience.org/library/papers/33034426PubMed
2025271708The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.Nat Commun2014https://conductscience.org/library/papers/25271708PubMed

See all 196 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
41328404Dual Regulation and Clinical Application of miR-34 in Virus-Related Tumors Through Anti-Viral Immunity and Tumor Suppression.Drug Des Devel Ther2025https://conductscience.org/library/papers/41328404PubMed
41228232Masters of Gene Expression: Transcription Factors in Pediatric Cancers.Cancers (Basel)2025https://conductscience.org/library/papers/41228232PubMed
40317918Delving Into Retinoblastoma Genetics: Discovery of Novel Mutations and Their Clinical Impact: Retrospective Cohort Study.Cancer Med2025https://conductscience.org/library/papers/40317918PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MDM24193PubTator's text mininghttps://conductscience.org/library/genes/4193NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
MYCN4613PubTator's text mininghttps://conductscience.org/library/genes/4613NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39802403

GET https://conductscience.org/api/papers/v1/39802403/references?page=2